RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma
Recruiting
Phase 4
Interventional Study
Melanoma Advanced
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 4
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 110 (estimated)
- Sponsor
- Fudan University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This study is a prospective, open-label, multicenter, real-world clinical study to evaluate the efficacy and safety of tunlametinib in patients with NRAS-mutant advanced melanoma who have failed prior anti-PD-1/PD-L1 therapy.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Aged ≥18 years (inclusive), male or female;
* Patients with histologically or cytologically confirmed locally advanced or metastatic melanoma;
* Prior genetic testing results showing positive NRAS mutation;
* Patients who have failed prior anti-PD-1/PD-L1 therapy;
* Able to ta…
Contacts